BMJ  2005;330:1035-1036 (7 May), doi:10.1136/bmj.330.7499.1035

Editorial

The polypill and cardiovascular disease

May be appropriate for secondary, but perhaps not for primary prevention

The first 150 words of the full text of this article appear below.

The prevention of cardiovascular disease with drug therapy is well known. Randomised controlled trials and meta-analyses of trials of lipid and blood pressure lowering and antiplatelet therapy have established their efficacy in the prevention of cardiovascular diseases. Wald and Law have proposed that these three treatments, along with folic acid, be combined into a "polypill."¹ They propose a combined strategy for primary and secondary prevention—targeting all people with pre-existing cardiovascular disease (secondary prevention) but more controversially, targeting all adults aged over 55 (primary prevention) as well. The underlying assumption concerning the efficacy of this strategy is that the six individual ingredients of the polypill (thiazide diuretic, angiotensin converting enzyme inhibitor, blocker, statin, aspirin, and folic acid) when combined together have synergistic treatment effects—calculated by multiplying the relative risk reductions on each class of treatment. Their polypill strategy has generated worldwide interest, with some critics questioning this underlying multiplicative assumption . . . [Full text of this article]

Tayside Centre for General Practice, University of Dundee, Dundee DD2 4AD

Department of Social Medicine, University of Bristol, Bristol BS8 2PR

Department of Social Medicine, University of Bristol, Bristol BS8 2PR

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Hit parade
BMJ 2005 331: 115. [Extract] [Full Text]

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

Julia Hippisley-Cox and Carol Coupland
BMJ 2005 330: 1059-1063. [Abstract] [Full Text] [PDF]

Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials

Li Wei, Shah Ebrahim, Christopher Bartlett, Peter D Davey, Frank M Sullivan, and Thomas M MacDonald
BMJ 2005 330: 821. [Abstract] [Full Text] [PDF]

A strategy to reduce cardiovascular disease by more than 80%

N J Wald and M R Law
BMJ 2003 326: 1419. [Abstract] [Full Text] [PDF]

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

David S Wald, Malcolm Law, and Joan K Morris
BMJ 2002 325: 1202-1206. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• DeWilde, S, Carey, I M, Richards, N, Whincup, P H, Cook, D G (2008). Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 94: 83-88 [Abstract] [Full text]  
• (2005). Hit parade. BMJ 331: 115-115 [Full text]